Comparative Pharmacology
Head-to-head clinical analysis: A HYDROCORT versus CORTIFOAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A HYDROCORT versus CORTIFOAM.
A-HYDROCORT vs CORTIFOAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
None Documented
None Documented
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Category C
Category C
Corticosteroid
Corticosteroid